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 Abstract 
 
Patients often have lower (white coat effect) or higher (masked effect) ambulatory/home 
blood pressure readings compared to clinic measurements, resulting in misdiagnosis of 
hypertension. The present study assessed whether blood pressure and patient characteristics 
from a single clinic visit can accurately predict the difference between ambulatory/home and 
clinic blood pressure readings (the ‘home-clinic difference’). A linear regression model 
predicting the home-clinic blood pressure difference was derived in two datasets measuring 
automated clinic and ambulatory/home blood pressure (n=991) using candidate predictors 
identified from a literature review. The model was validated in four further datasets 
(n=1,172) using Area Under the Receiver Operator Characteristic curve analysis. A masked 
effect was associated with male sex, a positive clinic blood pressure change (difference 
between consecutive measurements during a single visit) and a diagnosis of hypertension. 
Increasing age, clinic blood pressure level and pulse pressure were associated with a white 
coat effect. The model showed good calibration across datasets (Pearson’s correlation 0.48-
0.80) and performed well predicting ambulatory hypertension (AUROC 0.75, 95%CI 0.72-
0.79 [systolic]; 0.87, 95%CI 0.85-0.89 [diastolic]). Used as a triaging tool for ambulatory 
monitoring, the model improved classification of a patient’s blood pressure status compared 
with other guideline recommended approaches (93% [92-95%] classified correctly; US 73% 
[70-75%]; Canada 74% [71-77%]; UK 78% [76-81%]). This study demonstrates that patient 
characteristics from a single clinic visit can accurately predict a patient’s ambulatory blood 
pressure. Utilisation of this prediction tool for triaging of ambulatory monitoring could result 
in more accurate diagnosis of hypertension and hence more appropriate treatment. 
 
Word count: 250 
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 Background 
High blood pressure (hypertension) is an important risk factor for cardiovascular disease, a 
significant cause of morbidity and mortality worldwide.1 The diagnosis and management of 
hypertension depends on accurate measurement of blood pressure so that antihypertensive 
treatment can be targeted appropriately and unnecessary adverse effects and healthcare costs 
can be avoided.2 Traditionally, blood pressure measurement has taken place in the Primary 
Care Physician’s office or clinic using an electronic oscillometric or aneroid 
sphygmomanometer (clinic blood pressure, table 1), but it has long been recognised that 
home or ambulatory (out-of-office) blood pressures provide more accurate estimates of a 
patient’s true mean blood pressure.3 This is in part, because multiple readings are taken and it 
correlates with a range of cardiovascular outcomes and end-organ damage better than clinic 
blood pressure.4, 5 
 
Clinic blood pressure values are often different from out-of-office blood pressure and can 
lead to incorrect classification of blood pressure status and hence inappropriate 
management.6, 7 Patients with higher clinic blood pressure than the corresponding out-of-
office pressure will have a negative home-clinic blood pressure difference (white coat effect) 
and are at risk of over-treatment (see supplemental material, figure S1).8 Conversely, patients 
with higher out-of-office blood pressures than would be expected from the corresponding 
clinic blood pressure have a positive home-clinic blood pressure difference (masked effect), 
and often remain unrecognised and therefore potentially under-treated (supplemental 
material, figure S1).9 Such patients are at increased risk of target organ damage10 and have 
cardiovascular morbidity and mortality not dissimilar to sustained hypertension.11 
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 Strategies to reduce these misclassifications are emerging and include the use of multiple 
automated clinic blood pressure readings which have been shown to reduce the white coat 
effect.12, 13 In the US, the Preventive Services Task Force14 have recently released guidelines 
recommending that home or ambulatory blood pressure monitoring is used to confirm a 
diagnosis of hypertension, an approach which has already been adopted in the UK,15 where it 
is considered cost-effective due to a reduction in misdiagnosis caused by the white coat 
effect.2 However, this approach will result in some patients with sustained hypertension 
identified by clinic blood pressure readings being sent for arguably unnecessary out-of-office 
monitoring, which some patients find uncomfortable, and importantly, this strategy will not 
capture those patients with masked hypertension. 
 
Recent work by some of the authors has shown that the change in clinic blood pressure over 
multiple automated clinic readings from a single visit can predict the home-clinic blood 
pressure difference.16 This study aimed to use patient characteristics and details of repeated 
clinic blood pressure measurements to derive a model for predicting this home-clinic blood 
pressure difference. Further, we aimed to validate this model and examine its application as a 
means to target ambulatory blood pressure monitoring more efficiently in routine clinical 
practice. 
 
Methods 
An extended version of the methods is available in the supplemental material. Blood pressure 
definitions and terminology used are summarised in table 1. 
 
Study design and source data 
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 The present study was an individual patient data analysis of cohort studies conducted in a 
Primary Care setting.12, 17-21 A linear regression model predicting the home-clinic blood 
pressure difference was derived in two datasets using candidate predictors identified from a 
literature review. All included studies collected relevant data including clinic, home and/or 
daytime ambulatory blood pressure readings using a validated electronic oscillometric blood 
pressure monitor and details of patient characteristics and medical history. The characteristics 
of patients from included studies are detailed in table 2. Individual clinic readings were 
available in each study permitting estimation of a variety of different definitions of clinic 
blood pressure. Patients in the CAMBO study12 had their clinic blood pressure measured with 
a BpTRU device with either the doctor or nurse taking the first reading and then leaving the 
room for the remaining measurements. In all other studies, multiple clinic readings were 
taken in the presence of a nurse or practice reception staff.17-20 Since our study involved 
secondary analysis of existing data, it was not possible to standardise protocols for blood 
pressure measurement across studies and specific protocols for the measurement of home and 
daytime ambulatory blood pressure did vary to some degree (for details see supplemental 
material, table S1). 
 
Patients were selected for the derivation cohort from the BP-Eth17 and TASMINH219 studies 
(n=991) because these were considered to be sufficiently large and representative of the 
population likely to undergo blood pressure monitoring for diagnosis and management of 
hypertension. Patients from the remaining four studies12, 18, 20, 21 were utilised in the validation 
cohort (n=1,172). 
 
Statistical Analysis 
Selection of candidate predictors 
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 Candidate predictors considered for inclusion in the model were identified by literature 
review.22 Of the 60 identified, a total of 14 variables were considered for inclusion in the 
model, including age, sex, body mass index, diagnosis of hypertension and time since 
diagnosis, antihypertensive prescription, smoking status, alcohol consumption, diagnosis of 
cardiovascular disease, clinic blood pressure level (systolic/diastolic) and multiple clinic 
blood pressure characteristics defined as previously described.16 These characteristics were 
the difference between the first and last clinic blood pressure reading (referred to as the 
‘clinic blood pressure change’ [estimated from 3 or 6 readings]), the rate of the change in 
clinic blood pressure (referred to as the ‘blood pressure slope’ [estimated from 3 or 6 
readings]) and the ‘curvature’ of this change in clinic blood pressure (referred to as the ‘blood 
pressure quadratic’ [estimated from 6 readings]). Age, sex and clinic blood pressure variables 
were included in the final model a priori because they were cited as significant predictors of 
white coat or masked hypertension in more than twice as many published studies compared to 
other predictors in a previous literature review.22, 23 Backwards stepwise selection was used to 
select the remaining candidate predictors for the final model. Only predictors reaching a 
significance level of p <0.05 were included. 
 
Model derivation 
A complete case analysis was conducted due to low amounts of missing data. Two separate 
linear regression models were constructed examining factors that predict the systolic and 
diastolic home-clinic blood pressure difference (1st clinic blood pressure reading minus mean 
out-of-office blood pressure). Out-of-office blood pressure was taken to be mean daytime 
ambulatory blood pressure where available, otherwise mean home blood pressure was used 
(table 1).19, 20 Due to co-linearity between some of the candidate predictors listed above, 
separate models were compared in three stages using likelihood ratio tests. The best fitting 
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 model at each stage was considered in the next stage and where there was no significant 
difference in model fit, the most parsimonious model was selected. Stage one compared five 
different prediction models examining combinations of clinic blood pressure characteristic. 
Stage two compared the best fitting model from the first step using different definitions of 
clinic blood pressure (1st clinic reading; mean of 1-3 readings; mean of 2-3 readings; mean of 
1-6 readings; or the mean of 2-6 readings). The final stage explored pre-specified interactions 
of all candidate predictors with age, sex and diagnosis of hypertension and the interaction 
between clinic blood pressure and the characteristics of the change in clinic blood pressure. 
Ninety-five percent confidence intervals (CIs) for model coefficients were estimated with 
bootstrap resampling (200 replications). Model coefficients are presented for centred 
continuous variables in the final model. 
 
Model validation and performance 
The agreement between predicted and actual home-clinic blood pressure differences was 
examined in both derivation and validation cohorts using Pearson’s correlation coefficient 
and Bland-Altman plots. A ‘model-adjusted’ clinic blood pressure value was calculated by 
combining the original clinic pressure (1st clinic reading) with the home-clinic blood pressure 
difference estimated from the model. The ability of the ‘model-adjusted’ clinic blood 
pressure to predict out-of-office hypertension was assessed using Area Under the Receiver 
Operator Characteristic (AUROC) curve statistics. High AUROC values (up to 1) indicate 
better model discrimination.  
 
Potential strategies for referral for out-of-office monitoring were explored in the derivation 
cohort (supplemental material, tables S2 and S3), with the optimal strategy defined as a 
threshold which produced an overall classification error of <10% with the lowest proportion 
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 of patients referred for out-of-office monitoring. Model performance detecting true out-of-
office hypertension was compared to existing strategies for blood pressure measurement 
described in international hypertension guidelines (supplemental material, table S4).15, 24-26 
The model was also applied to a nominal population from our validation cohort, with a 
comparable distribution of clinic blood pressures to that documented in the Health Survey for 
England. Using this nominal population, the number of patients being correctly diagnosed 
with hypertension per 1,000 individuals was compared to the current NICE diagnostic 
algorithm15 (considered best of the rest).  
 
Sensitivity analyses explored the model performance by individual study, predicting home or 
daytime ambulatory blood pressure, in patients with raised clinic blood pressure and those 
with controlled or normal clinic blood pressure. Were also examined a revised diagnostic 
strategy which does not utilise the PROOF-BP algorithm, but in which patients with a clinic 
blood pressure between 130/85mmHg and 160/100mmHg were referred for out-of-office 
monitoring. All sensitivity analyses were conducted in the validation cohort (except those by 
individual study which compared all available data). 
 
All analyses were performed in STATA version 13.1 (MP parallel edition, StataCorp, Texas, 
USA). Data are presented as proportions of the total study population or means with standard 
deviation or 95% CIs unless otherwise stated. Ethical approval was given for all individual 
studies contributing data but approval for secondary analysis using anonymised data was not 
required. 
 
Results 
Characteristics of the study cohort 
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 Of the 2,470 patients with out-of-office blood pressure measurements enrolled across the six 
studies, relevant data were available for analysis in a total of 2,163 patients (991 patients in 
the derivation cohort; 1,172 patients in the validation cohort). Relevant data were not 
available in some patients enrolled in the CAMBO study12 because not all centres recorded 
the individual automated clinic blood pressure readings required for this analysis (table 2, 
table S1). Characteristics of the derivation and validation cohorts were similar in terms of 
age, sex, the prevalence of systolic white coat hypertension and systolic masked hypertension 
(see supplemental material, table S5). 
 
 
Model derivation 
Goodness-of-fit was similar between models examining three or six clinic blood pressure 
readings (derivation stage 1; adjusted R2 0.50-0.52) and those using different definitions of 
clinic blood pressure (derivation stage 2; adjusted R2 0.50-0.52). The most parsimonious 
model selected at each stage was that which utilised patient characteristics along with the 
clinic blood pressure change (estimated from three clinic readings), with the 1st clinic reading 
as an estimate of clinic blood pressure. 
 
The systolic masked effect (a positive home-clinic difference) was associated with male sex, 
a positive clinic blood pressure change and a previous diagnosis of hypertension (figure 1). 
The same factors were predictive of a diastolic masked effect with the exception of male sex. 
The systolic white coat effect (negative home-clinic blood pressure difference) was 
associated with increasing clinic blood pressure only (figure 1). The diastolic white coat 
effect was associated with increasing clinic blood pressure, increasing age and increasing 
pulse pressure. The final model included significant interactions between age, sex, clinic 
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 blood pressure, the clinic blood pressure change, pulse pressure, BMI, history of 
cardiovascular disease, presence of an antihypertensive prescription, history of hypertension 
and duration of hypertension. The final model (centred) coefficients are presented in table 3 
and the full equation is given in the supplemental material (figure S6). 
 
Model validation and performance 
The final model showed good calibration across all derivation and validation datasets 
(Pearson’s correlation 0.62-0.80 [systolic]; 0.48-0.80 [diastolic]; p<0.001) (supplemental 
material, figures S2 and S3). At the extremes of home-clinic blood pressure difference the 
model was less accurate, as evidenced by the slight skew observed in the Bland-Altman plots 
(supplemental material, figures S4 and S5), suggesting the model under-predicts those with a 
large masked effect and over-predicts those with a large white coat effect. 
 
The model was good at discriminating out-of-office hypertension (masked or sustained 
hypertension) in the derivation cohort (AUROC 0.80, 95% CI 0.78-0.83 [systolic model]; 
0.82, 95% CI 0.80-0.85 [diastolic model]) and this discrimination was maintained in the 
validation cohort (AUROC 0.75, 95% CI 0.72-0.79 [systolic model]; 0.87, 95% CI 0.85-0.89 
[diastolic model]) (figure 2). Using the ‘model-adjusted’ clinic blood pressure, the optimal 
thresholds for referral for out-of-office monitoring were >130/80mmHg and <145/90mmHg. 
In other words, below a ‘model-adjusted’ blood pressure of 130/80mmHg, patients were 
confidently predicted as normotensive and those with a ‘model-adjusted’ blood pressure of 
145/90mmHg or greater were considered hypertensive. Anyone with a ‘model-adjusted’ 
blood pressure between the two required out-of-office measurements. Using this model-
adjusted blood pressure to triage patients for out-of-office monitoring, 93% of cases were 
correctly classified. This was an improvement of up to 29% compared to strategies 
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 recommended in current clinical guidelines (PROOF-BP 93% [92-95%]; AHA 73% [70-
75%]; CHEP 74% [71-77%]; ESH 73% [70-75%]; NICE 78% [76-81%]) with similar 
utilisation of out-of-office monitoring (PROOF-BP, 58% referred [55-61%]; vs. NICE, 54% 
referred, [51-57%]) (table 4). In a nominal representative population, for every 1,000 people 
aged 45-74 years screened with the new algorithm, correct classification would be gained for 
910 patients with 395 diagnosed as hypertensive, compared with the next best strategy (NICE 
algorithm) where 853 would be correctly classified and only 274 diagnosed as hypertensive. 
The additional 121 diagnoses of hypertension result from the detection of those patients with 
masked hypertension. 
 
Sensitivity analyses 
The results of the sensitivity analyses are detailed in the online appendix (supplemental 
material, table S6). Model performance was consistent across individual studies (AUROC 
0.61-0.78 [systolic model]; 0.74-0.91 [diastolic model]) and the new algorithm resulted in 
better targeting of out-of-office blood pressure compared to a revised diagnostic strategy 
using clinic blood pressure alone to triage patients for out-of-office monitoring. Using the 
new algorithm to triage only those patients with raised clinic blood pressure (i.e. only 
considering those patients with a potential white coat effect) resulted in correct classification 
of 94% of patients with only 45% requiring out-of-office monitoring (see supplemental 
material, table S6).  
 
Discussion 
This study describes a clinical prediction model which combines patient characteristics (age, 
sex, BMI, history of hypertension, cardiovascular disease and antihypertensive treatment) and 
three clinic blood pressure measurements from a single visit to accurately predict a patient’s 
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 out-of-office blood pressure. Used as a triaging tool for out-of-office monitoring, detection of 
hypertension or uncontrolled blood pressure was markedly improved from existing diagnostic 
and management strategies, specifically including those with hitherto unrecognised masked 
hypertension. 
 
Strengths and limitations 
This retrospective study utilised a large cohort of patients from six previous studies providing 
a population representative of patients across the UK and North America undergoing blood 
pressure measurement in Primary Care. Sensitivity analyses revealed consistent model 
performance across individual studies, suggesting that it would be effective regardless of the 
electronic blood pressure monitoring device (BpTRU, Stabil-O-Graph) or measurement 
protocol used (rest period vs. no rest period; nurse present during measurement vs. nurse not 
present; automatic readings vs. patient/nurse initiated readings; 1 minute vs. 2 minute 
intervals between readings). It is well known that blood pressure measurements made under 
controlled conditions in a research setting are not necessarily comparable to those made by a 
physician in routine clinical practice.24, 27, 28 Differences occur for a variety of reasons, 
including the use of inadequate or uncalibrated devices29-31 and suboptimal measurement 
techniques.32-34 Indeed, the present algorithm requires three consecutive blood pressure 
readings to be taken at a single clinic visit and whilst this is recommended in most 
hypertension guidelines,15, 24-26 ensuring this approach is adhered to in routine practice may 
require some education of physicians and nurses. Therefore, although this prediction model is 
shown to be accurate in a research setting, is not guaranteed to work in routine clinical 
practice and prospective validation of the PROOF-BP prediction tool in a clinical setting 
warrants further investigation. 
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 Bland-Altman plots demonstrated that the PROOF-BP prediction model tends to 
underestimate those with a large masked effect and overestimate those with a large white coat 
effect. This is likely to be explained by the underlying population in the derivation cohort 
which contained a higher proportion of hypertensive (defined by clinic readings) patients on 
treatment (704 [71%]), a population known to have an exaggerated white coat effect 
compared to normotensives (supplemental material, figure S1).35 Whilst the model was less 
accurate at extremes of home-clinic blood pressure difference, it showed good performance 
detecting out-of-office hypertension around the clinical threshold (140/90mmHg) where the 
average home-clinic blood pressure difference is smaller.35 
 
The present analyses used home blood pressure data to define out-of-office blood pressure 
where daytime ambulatory measurements were not available (table 1). Some argue that 24-
hour ambulatory blood pressure should be used as the ‘gold standard’ measure of blood 
pressure,26 because it contains information about night-time blood pressure which includes 
additional prognostic information. However, the recent review by the US Preventive Services 
Task Force found no apparent difference among 24-hour, daytime, and night-time ambulatory 
blood pressure measurement protocols for prediction of cardiovascular outcomes14 and a 
sensitivity analysis in the present study demonstrated no change in the accuracy of the 
PROOF-BP prediction model using home or daytime ambulatory readings. 
 
Comparison with previous literature 
Many studies have examined the association between patient characteristics and the home-
clinic blood pressure difference, noting age,36-38 sex36-39 and clinic blood pressure level,36-39 
along with anxiety,40, 41 stress42 and other factors22 as significant independent predictors of 
white coat or masked hypertension. The findings of the present study were consistent with 
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 previous literature, showing age, sex, clinic blood pressure, pulse pressure and a history of 
hypertension as significant predictors of the home-clinic blood pressure difference. 
Interestingly, female sex was not a significant predictor of the white coat effect, although it 
was included a priori in the final prediction model since this association has been well 
defined in the previous literature.36, 38 
 
Few studies have suggested a strategy for targeted use of out-of-office blood pressure in 
routine clinical practice. Myers43 and Godwin et al.,44 have proposed the use of multiple 
(automated) office blood pressure readings taken using the BpTRU device to identify patients 
high normal blood pressure (130/80mmHg to 139/89mmHg) who could be referred for 
ambulatory blood pressure to confirm the presence of masked hypertension. Similarly, Viera 
et al.,45 examined optimal automated clinic blood pressure levels for referral for out-of-office 
monitoring in patients with normal clinic pressure for detection of masked hypertension. 
However, they concluded that using clinic blood pressure alone was not sufficient, because of 
high referral rates, and suggested that a combination of factors, including patient 
characteristics might be more effective at targeting out-of-office blood pressure more 
efficiently. 
 
Implications for clinical practice 
The US Preventive Services Task Force14 recently released guidelines recommending that 
ambulatory blood pressure monitoring is used to confirm a diagnosis of hypertension. It is 
anticipated that these guidelines will follow a similar approach to that advocated in the UK 
by NICE, which does not capture those patients with masked hypertension. The present 
analyses propose a method for capturing nearly all patients with truly raised out-of-office 
blood pressure which is likely to result in a small increase in the amount of out-of-office 
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 monitoring required in routine practice but could still be very cost-effective if it reduces the 
current best practice involving indiscriminate application of ambulatory monitoring.2, 14, 15  
Indeed, our sensitivity analyses show that in patients with raised clinic readings, the PROOF-
BP prediction model could potentially reduce the proportion of referrals for daytime 
ambulatory monitoring by over half to 285/629 (45%), with nearly all patients being 
accurately diagnosed (589/629 [94%] correctly classified) and acceptable false positive and 
false negative rates (6% and 0% respectively). Importantly, this new method identifies 
patients with possible masked hypertension which is otherwise unsuspected unless there is 
evidence of unexpected end organ damage. 
 
An algorithm for using the PROOF-BP prediction tool in routine clinical practice is presented 
in figure 3. Electronic blood pressure monitors which take up to three consecutive readings 
(at 1 minute intervals) are now cheap and routinely available, permitting utilisation of this 
algorithm before, during or after a standard physician consultation in Primary Care. The 
prediction model could easily be incorporated into general practice computer systems, 
accessed as an online calculator or even built into smartphones linked to blood pressure 
monitors to facilitate implementation in routine clinical practice. This novel approach to 
measurement and management would require ‘buy in’ from both patients and practitioners 
and therefore some degree of education may be required during implementation. 
 
Perspectives 
The present study shows that a combination of simple patient characteristics with three clinic 
blood pressure measurements from a single visit can accurately identify those patients 
requiring out-of-office blood pressure monitoring for suspected white coat and arguably most 
importantly masked hypertension. This prediction model has the potential improve the 
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 accuracy of diagnosis and management of hypertension in Primary Care and prospective 
validation in routine clinical practice along with analysis of cost-effectiveness are now 
warranted.  
17 
 
 Acknowledgements 
We would like to thank the researchers, patients and practices that took part in the original 
BP-Eth, CAMBO, HITS, Oxford self-monitoring study, TASMINH2 and TASMINH-SR 
studies without whom this work would not have been possible. We would also like to thank 
Roger Holder and David Yeomans for their assistance and support during the original 
conception, design and dissemination of this study.   
 
Funding Sources 
This work was funded by an Medical Research Council (MRC) Strategic Skills Post-doctoral 
Fellowship (MR/K022032/1) held by JS, with support from a National Institute for Health 
Research (NIHR) Programme Grant (RP-PG-1209–10051). RJMcM holds an NIHR 
Professorship and leads the self-management theme of the NIHR Oxford CLAHRC. BW is a 
NIHR Senior Investigator and his research is supported by the NIHR UCL Hospitals 
Biomedical Research Centre. FDRH is part funded as Director of the National Institute for 
Health Research (NIHR) School for Primary Care Research (SPCR), Theme Leader of the 
NIHR Oxford Biomedical Research Centre (BRC), and Director of the NIHR Collaboration 
for Leadership in Applied Health Research and Care (CLAHRC) Oxford. The views and 
opinions expressed are those of the authors and do not necessarily reflect those of the MRC, 
NHS, NIHR, or the Department of Health.  
 
Declaration of competing interests: RJMcM has received equipment for research purposes 
from Omron and Lloyds Healthcare. CH has received expenses and payments for his media 
work from Channel 4, BBC, FreshOne TV productions and the Guardian, and also expenses 
from the WHO and the US FDA. He is also an expert witness in an ongoing medical device 
legal case, has received payment from BUPA for analyzing and appraising guidelines and 
18 
 
 income from the publication of a series of toolkit books published by Blackwells. FDRH has 
received limited research support in terms of blood pressure devices from Microlife and 
BpTRU. BW works in academic collaboration with Healthstats, Singapore, in developing 
novel blood pressure monitoring approaches. All other authors report no other relevant 
conflicts of interest.  
19 
 
 References 
1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual 
blood pressure to vascular mortality: a meta-analysis of individual data for one million 
adults in 61 prospective studies. Lancet. 2002;360:1903-1913. 
2. Lovibond K, Jowett S, Barton P, Caulfield M, Heneghan C, Hobbs FD, Hodgkinson J, 
Mant J, Martin U, Williams B, Wonderling D, McManus RJ. Cost-effectiveness of 
options for the diagnosis of high blood pressure in primary care: a modelling study. 
Lancet. 2011;378:1219-1230. 
3. Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den Hond E, McCormack 
P, Staessen JA, O'Brien E. Superiority of ambulatory over clinic blood pressure 
measurement in predicting mortality: the Dublin outcome study. Hypertension. 
2005;46:156-161. 
4. Ohkubo T, Hozawa A, Nagai K, Kikuya M, Tsuji I, Ito S, Satoh H, Hisamichi S, Imai Y. 
Prediction of stroke by ambulatory blood pressure monitoring versus screening blood 
pressure measurements in a general population: the Ohasama study. Journal of 
Hypertension. 2000;18:847-854. 
5. Staessen JA, Thijs L, Fagard R, O'Brien ET, Clement D, de Leeuw PW, Mancia G, 
Nachev C, Palatini P, Parati G, Tuomilehto J, Webster J. Predicting cardiovascular risk 
using conventional vs ambulatory blood pressure in older patients with systolic 
hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA. 1999;282:539-
546. 
6. Hodgkinson J, Mant J, Martin U, Guo B, Hobbs FD, Deeks JJ, Heneghan C, Roberts N, 
McManus RJ. Relative effectiveness of clinic and home blood pressure monitoring 
20 
 
 compared with ambulatory blood pressure monitoring in diagnosis of hypertension: 
systematic review. BMJ. 2011;342:d3621. 
7. Jin Y, Bies R, Gastonguay MR, Stockbridge N, Gobburu J, Madabushi R. 
Misclassification and discordance of measured blood pressure from patient's true blood 
pressure in current clinical practice: a clinical trial simulation case study. Journal of 
Pharmacokinetics and Pharmacodynamics. 2012;39:283-294. 
8. Pickering TG, Coats A, Mallion JM, Mancia G, Verdecchia P. Blood Pressure 
Monitoring. Task force V: White-coat hypertension. Blood Pressure Monitoring. 
1999;4:333-341. 
9. Pickering TG, Davidson K, Gerin W, Schwartz JE. Masked hypertension. Hypertension. 
2002;40:795-796. 
10. Sega R, Trocino G, Lanzarotti A, Carugo S, Cesana G, Schiavina R, Valagussa F, 
Bombelli M, Giannattasio C, Zanchetti A, Mancia G. Alterations of cardiac structure in 
patients with isolated office, ambulatory, or home hypertension: Data from the general 
population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study). 
Circulation. 2001;104:1385-1392. 
11. Ohkubo T, Kikuya M, Metoki H, Asayama K, Obara T, Hashimoto J, Totsune K, Hoshi 
H, Satoh H, Imai Y. Prognosis of "masked" hypertension and "white-coat" hypertension 
detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the 
Ohasama study. Journal of the American College of Cardiology. 2005;46:508-515. 
12. Myers MG, Godwin M, Dawes M, Kiss A, Tobe SW, Grant FC, Kaczorowski J. 
Conventional versus automated measurement of blood pressure in primary care patients 
21 
 
 with systolic hypertension: randomised parallel design controlled trial. BMJ. 
2011;342:d286. 
13. Myers MG, Valdivieso M, Kiss A. Use of automated office blood pressure measurement 
to reduce the white coat response. Journal of Hypertension. 2009;27:280-286. 
14. Piper MA, Evans CV, Burda BU, Margolis KL, O'Connor E, Whitlock EP. Diagnostic 
and predictive accuracy of blood pressure screening methods with consideration of 
rescreening intervals: a systematic review for the U.S. Preventive Services Task Force. 
Annals of Internal Medicine. 2015;162:192-204. 
15. National Clinical Guideline Centre. National Institute for Health and Clinical Excellence 
Guidance (CG127). Hypertension: The Clinical Management of Primary Hypertension in 
Adults: Update of Clinical Guidelines 18 and 34. London: Royal College of Physicians 
(UK); 2011(CG127). 
16. Sheppard JP, Holder R, Nichols L, Bray E, Hobbs FD, Mant J, Little P, Williams B, 
Greenfield S, McManus RJ. Predicting out-of-office blood pressure level using repeated 
measurements in the clinic: an observational cohort study. Journal of Hypertension. 
2014;32:2171-2178; discussion 2178. 
17. Martin U, Haque MS, Wood S, Greenfield SM, Gill PS, Mant J, Mohammed MA, Heer 
G, Johal A, Kaur R, Schwartz C, McManus RJ. Ethnicity and Differences Between 
Clinic and Ambulatory Blood Pressure Measurements. American Journal of 
Hypertension. 2015;28:729-738. 
18. McKinstry B, Hanley J, Wild S, Pagliari C, Paterson M, Lewis S, Sheikh A, Krishan A, 
Stoddart A, Padfield P. Telemonitoring based service redesign for the management of 
22 
 
 uncontrolled hypertension: multicentre randomised controlled trial. BMJ. 
2013;346:f3030. 
19. McManus RJ, Mant J, Bray EP, Holder R, Jones MI, Greenfield S, Kaambwa B, Banting 
M, Bryan S, Little P, Williams B, Hobbs FD. Telemonitoring and self-management in 
the control of hypertension (TASMINH2): a randomised controlled trial. Lancet. 
2010;376:163-172. 
20. McManus RJ, Mant J, Haque MS, et al. Effect of self-monitoring and medication self-
titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular 
disease: the TASMIN-SR randomized clinical trial. JAMA. 2014;312:799-808. 
21. Nunan D, Thompson M, Heneghan C, Perera R, McManus RJ, Ward AM. Accuracy of 
self-monitored blood pressure for diagnosing hypertension in primary care. Journal of 
Hypertension. 2015;33:755-762. 
22. Sheppard JP, Fletcher B, Gill P, Martin U, Roberts N, McManus RJ. Predictors of the 
Home-Clinic Blood Pressure Difference: A Systematic Review and Meta-Analysis. 
American Journal of Hypertension. Epub 2015 Sep 22. pii: hpv157 
23. Steyerberg EW. Restriction on candidate predictors. Clinical Prediction Models. New 
York: Springer Science+Business Media; 2010: 175-187. 
24. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, 
Sheps SG, Roccella EJ. Recommendations for blood pressure measurement in humans 
and experimental animals: part 1: blood pressure measurement in humans: a statement 
for professionals from the Subcommittee of Professional and Public Education of the 
American Heart Association Council on High Blood Pressure Research. Circulation. 
2005;111:697-716. 
23 
 
 25. Dasgupta K, Quinn RR, Zarnke KB, et al. The 2014 Canadian Hypertension Education 
Program recommendations for blood pressure measurement, diagnosis, assessment of 
risk, prevention, and treatment of hypertension. The Canadian Journal of Cardiology. 
2014;30:485-501. 
26. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management 
of arterial hypertension: the Task Force for the Management of Arterial Hypertension of 
the European Society of Hypertension (ESH) and of the European Society of Cardiology 
(ESC). European Heart Journal. 2013;34:2159-2219. 
27. Sebo P, Pechere-Bertschi A, Herrmann FR, Haller DM, Bovier P. Blood pressure 
measurements are unreliable to diagnose hypertension in primary care. Journal of 
Hypertension. 2014;32:509-517. 
28. Myers MG, Godwin M, Dawes M, Kiss A, Tobe SW, Kaczorowski J. Measurement of 
blood pressure in the office: recognizing the problem and proposing the solution. 
Hypertension. 2010;55:195-200. 
29. Rouse A, Marshall T. The extent and implications of sphygmomanometer calibration 
error in primary care. Journal of Human Hypertension. 2001;15:587-591. 
30. Coleman AJ, Steel SD, Ashworth M, Vowler SL, Shennan A. Accuracy of the pressure 
scale of sphygmomanometers in clinical use within primary care. Blood Pressure 
Monitoring. 2005;10:181-188. 
31. A'Court C, Stevens R, Sanders S, Ward A, McManus R, Heneghan C. Type and accuracy 
of sphygmomanometers in primary care: a cross-sectional observational study. BJGP. 
2011;61:e598-603. 
24 
 
 32. Manzoli L, Simonetti V, D'Errico MM, De Vito C, Flacco ME, Forni C, La Torre G, 
Liguori G, Messina G, Mezzetti A, Panella M, Pizzi C, Siliquini R, Villari P, Cicolini G. 
(In)accuracy of blood pressure measurement in 14 Italian hospitals. Journal of 
Hypertension. 2012;30:1955-1960. 
33. McVicker JT. Blood pressure measurement--does anyone do it right?: An assessment of 
the reliability of equipment in use and the measurement techniques of clinicians. The 
Journal of Family Planning and Reproductive Health Care. 2001;27:163-164. 
34. Veiga EV, Nogueira MS, Carnio EC, Marques S, Lavrador MA, de Moraes SA, Souza 
LA, Lima NK, Nobre F. Assessment of the techniques of blood pressure measurement by 
health professionals. Arquivos Brasileiros de Cardiologia. 2003;80:83-9. 
35. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Zampi I, Gattobigio R, Sacchi N, 
Porcellati C. White coat hypertension and white coat effect. Similarities and differences. 
American Journal of Hypertension. 1995;8:790-798. 
36. Abir-Khalil S, Zaimi S, Tazi MA, Bendahmane S, Bensaoud O, Benomar M. Prevalence 
and predictors of white-coat hypertension in a large database of ambulatory blood 
pressure monitoring. Eastern Mediterranean Health Journal. 2009;15:400-407. 
37. Andalib A, Akhtari S, Rigal R, Curnew G, Leclerc JM, Vaillancourt M, Tardif JC. 
Determinants of masked hypertension in hypertensive patients treated in a primary care 
setting. Internal Medicine Journal. 2012;42:260-266. 
38. Lindbaek M, Sandvik E, Liodden K, Mjell J, Ravnsborg-Gjertsen K. Predictors for the 
white coat effect in general practice patients with suspected and treated hypertension. 
BJGP. 2003;53:790-793. 
25 
 
 39. Sobrino J, Domenech M, Camafort M, Vinyoles E, Coca A. Prevalence of masked 
hypertension and associated factors in normotensive healthcare workers. Blood Pressure 
Monitoring. 2013;18:326-331. 
40. Jhalani J, Goyal T, Clemow L, Schwartz JE, Pickering TG, Gerin W. Anxiety and 
outcome expectations predict the white-coat effect. Blood Pressure Monitoring. 
2005;10:317-319. 
41. Spruill TM, Pickering TG, Schwartz JE, Mostofsky E, Ogedegbe G, Clemow L, Gerin 
W. The impact of perceived hypertension status on anxiety and the white coat effect. 
Annals of Behavioral Medicine. 2007;34:1-9. 
42. MacDonald MB, Laing GP, Wilson MP, Wilson TW. Prevalence and predictors of 
white-coat response in patients with treated hypertension. CMAJ. 1999;161:265-269. 
43. Myers MG. A proposed algorithm for diagnosing hypertension using automated office 
blood pressure measurement. Journal of hypertension. 2010;28:703-708. 
44. Godwin M, Birtwhistle R, Delva D, Lam M, Casson I, MacDonald S, Seguin R. Manual 
and automated office measurements in relation to awake ambulatory blood pressure 
monitoring. Family Practice. 2011;28:110-117. 
45. Viera AJ, Lin FC, Tuttle LA, Shimbo D, Diaz KM, Olsson E, Stankevitz K, Hinderliter 
AL. Levels of Office Blood Pressure and Their Operating Characteristics for Detecting 
Masked Hypertension Based on Ambulatory Blood Pressure Monitoring. American 
Journal of Hypertension. 2015;28:42-49. 
  
26 
 
 Novelty and Significance 
 
What Is New? 
• This study shows a simple linear regression model incorporating patient 
characteristics and three consecutive clinic blood pressure measurements from a 
single clinic visit can accurately identify those patients requiring out-of-office blood 
pressure monitoring for suspected white coat or masked hypertension.  
• The model performance was consistent across populations, and studies using different 
blood pressure monitors and measurement techniques, suggesting the results are 
widely applicable across Primary Care.  
 
What Is Relevant? 
 
• This prediction model could be used as an online calculator or integrated into practice 
computer systems for triaging of out-of-office monitoring to permit detection of those 
patients with white coat or masked hypertension in routine clinical practice.  
• The present analyses suggest such an approach would improve the detection of 
hypertension and provide a strategy for capturing patients with apparent masked 
hypertension for the first time. 
 
Summary 
Our findings suggest that it is possible to predict which patients are most likely to display a 
white coat or masked effect, using patient characteristics and multiple clinic blood pressure 
measurements from a single clinic visit.  
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 Figure legends 
Figure 1. Coefficient plot showing predictors of the systolic and diastolic home-clinic blood 
pressure difference 
 
Panel A = Continuous predictors; Panel B = Binary predictors; BP=blood pressure; 
BMI=body mass index; CVD=cardiovascular disease.  
All coefficients are presented from the model prior to stepwise selection. 
Coefficients for continuous variables are presented as centred values per unit increase. 
 
Figure 2. Area under the receiver operator characteristic curve analysis showing performance 
of systolic/diastolic blood pressure prediction models for discrimination of out-of-office 
hypertension 
 
Panel A = systolic blood pressure (sBP) prediction model; Panel B = diastolic blood pressure 
(dBP) prediction model; AUROC = Area Under the Receiver Operator Characteristic curve. 
 
Figure 3. Algorithm for using the PROOF-BP prediction model to triage patients for out-of-
office blood pressure monitoring 
 
BP= Blood pressure; PROOF-BP=PRedicting Out-of-OFfice Blood Pressure in clinic tool; 
Existing strategies are based on the hypertension diagnostic pathway specified by the US 
Preventive Services Task Force and the National Institute for Health and Care Excellence.  
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 Tables 
Table 1. Definitions of blood pressure measurements described in the present study 
 
Term Definition 
Clinic blood pressure 1st clinic blood pressure reading from a single clinic 
visit using an electronic oscillometric 
sphygmomanometer 
Multiple clinic blood pressure 
readings 
3-6 clinic blood pressure readings from a single clinic 
visit using an automated oscillometric 
sphygmomanometer 
Clinic blood pressure change Difference between the 1st and 3rd (or 6th) clinic blood 
pressure reading taken in a single clinic visit using an 
automated oscillometric sphygmomanometer 
Daytime ambulatory blood pressure  Ambulatory blood pressure measured at 15-60 minute 
intervals during the daytime (definition of daytime and 
interval varies between studies) 
Home blood pressure Mean of 6 days of readings (2 readings per day taken 
in the morning) after discarding the 1st days' readings 
Out-of-office blood pressure Daytime ambulatory blood pressure or home blood 
pressure (if daytime ambulatory blood pressure is not 
available) 
Out-of-office hypertension Daytime ambulatory blood pressure or home blood 
pressure >135/85mmHg 
Home-clinic blood pressure 
difference 
The difference between out-of-office blood pressure 
and automated blood pressure measured in the clinic 
‘Model-adjusted’ clinic blood 
pressure 
1st clinic blood pressure reading added to the predicted 
home-clinic blood pressure difference (estimated by 
the PROOF-BP prediction algorithm). 
PROOF-BP = PRedicting Out-of-OFfice Blood Pressure in the clinic  
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 Table 2. Characteristics of studies used for model derivation and validation 
aHypertensive according to home or ambulatory blood pressure monitoring 
bDefined according to systolic blood pressure 
cStudies utilised for model derivation 
Study Author (year) 
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BP-Ethc Martin et al., (2014)17 771 771 59±10 
375 
(49%) 
 
Unselected 
 
81 
(11%) 
33 
(4%) 
130 
(17%) 
344 
(45%) 10±8 
484 
(63%) 
83 
(11%) 
136 
(19%) 
CAMBO Myers et al., (2011)12 555 379
d 64±10 131 (35%) 
Isolated 
systolic 
hypertensives 
0 
(0%) 
0 
(0%) 
0 
(0%) 
166 
(44%) 9±9 
364 
(96%) 
52 
(16%) 
64 
(19%) 
HITS Mckinstry et al., (2013)18 401 401 61±11 
237 
(59%) 
Uncontrolled 
hypertensives n/a 
0 
(0%) 
0 
(0%) 
379 
(95%) n/a 
352 
(88%) 
23 
(6%) 
42 
(10%) 
Oxford self-
monitoring 
study 
Nunan et al., 
(2015)21 
 
203 203 56±10 107 (53%) 
Untreated, 
clinic BP 
>130/80mmHg 
0 
(0%) 
0  
(0%) 
11 
(5%) 
109 
(54%) 0±0 
0     
(0%) 
67 
(33%) 
13 
(6%) 
TASMINH2c McManus et al., (2010)19 527 220
e 67±9 103 (47%) 
Uncontrolled 
hypertensives 
20 
(9%) 
12 
(5%) 
18 
(8%) 
172 
(78%) 10±8 
220 
(100%) 
42 
(21%) 
11 
(5%) 
TASMINH-
SR 
McManus et 
al., (2014)20 552 189
e 69±9 115 (61%) 
Uncontrolled, 
high risk 
hypertensives 
58 
(31%) 
30 
(16%) 
81 
(43%) 
134 
(71%) 11±9 
160 
(85%) 
18 
(10%) 
53 
(29%) 
30 
 
 
dPatients in the control arm (multiple clinic BP readings not taken); those recruited from centres where complete clinic BP readings were not 
documented 
ePatients in the control arm of the trial and those with missing home BP data 
CHD = Coronary heart disease; BP = blood pressure; SD = Standard deviation  
Hypertension defined as daytime out-of-office blood pressure (home or ambulatory monitoring) of >135/85mmHg. White coat systolic hypertension 
defined as a clinic blood pressure >140mmHg (mean of 2nd & 3rd readings) but an out-of-office blood pressure of <135mmHg. Masked systolic 
hypertension defined as a clinic blood pressure (mean of 2nd & 3rd readings) <140mmHg but an out-of-office blood pressure of >135mmHg. All 
percentages are given as a proportion of those patients with available data.  
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 Table 3. Linear regression model for prediction of the systolic/diastolic home-clinic blood pressure difference 
Model term 
Prediction model with interaction terms 
     Systolic prediction model    Diastolic prediction model 
ß 95% CI p value ß 95% CI p value 
Age (years)  0.07 -0.02 to 0.17  0.134 -0.33 -0.62 to -0.05  0.022 
Sex (male)  3.41  0.23 to 6.60  0.036  3.33  1.78 to 4.87 <0.001 
Clinic blood pressure (1st reading; mmHg) -0.50 -0.58 to -0.43 <0.001 -0.47 -0.51 to -0.42 <0.001 
Clinic blood pressure change (readings 1-3; mmHg)  0.36  0.26 to 0.46 <0.001  0.31  0.21 to 0.42 <0.001 
Body mass index (kg/m2) -0.21 -0.37 to -0.04  0.012 -0.07 -0.16 to 0.01  0.096 
Previous diagnosis of hypertension (yes) -5.07 -12.15 to 2.01  0.161 -0.03 -3.55 to 3.49  0.987 
Time since diagnosis of hypertension (years)  0.18  0.00 to 0.35  0.053    
Antihypertensive prescription (yes)  6.94  0.42 to 13.46  0.037  2.37 -1.30 to 6.04  0.206 
History of cardiovascular disease (yes)    -0.40 -1.69 to 0.89  0.543 
Pulse pressure (1st reading; mmHg) -0.04 -0.13 to 0.05  0.397 -0.06 -0.09 to -0.03 <0.001 
Age × clinic blood pressure -0.01 -0.01 to -0.00  0.027    
Age × pulse pressure  0.01  0.00 to 0.02  0.030    
Age × clinic blood pressure change     0.01  0.00 to 0.02  0.014 
Age × body mass index     0.01  0.00 to 0.02  0.039 
Age × history of cardiovascular disease     0.18  0.02 to 0.33  0.023 
Age × antihypertensive prescription at baseline    -0.13 -0.24 to -0.03  0.010 
Sex × body mass index  0.30  0.01 to 0.58  0.041    
Sex × time since diagnosis of hypertension -0.26 -0.50 to -0.02  0.034    
Sex × antihypertensive prescription at baseline -14.74 -23.33 to -6.15  0.001 -8.00 -12.45 to -3.54 <0.001 
Sex × previous diagnosis of hypertension  13.39  4.57 to 22.21  0.003  4.63  0.40 to 8.85  0.033 
Constant -9.09 -11.55 to -6.64 <0.001 -6.98 -8.24 to -5.72 <0.001 
CI = confidence intervals. ß coefficients and 95% confidence intervals given in mmHg. ß coefficients for continuous variables are presented as centred 
values per unit increase unless otherwise stated.   
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 Table 4. Comparison of model performance with current clinical practice in the validation cohort (n=1,100) 
Guideline 
(year) 
Systolic 
AUC 
(95% CI) 
Diastolic 
AUC 
(95% CI) 
Hypertensive 
(True positive) 
Normotensive 
(True negative) 
White coat 
hypertensive 
(False positive) 
Masked 
hypertensive 
(False negative) 
Correctly 
classified 
Referral 
for ABPM 
AHA (2005)24 
0.74 
(0.71-0.77) 
0.85 
(0.83-0.87) 
625 (57%) 173 (16%) 178 (16%) 124 (11%) 798 (73%) 0 (0%) 
CHEP (2014)25 
0.76 
(0.73-0.79) 
0.87 
(0.85-0.89) 
642 (58%) 172 (16%) 179 (16%) 107 (10%) 814 (74%) 0 (0%) 
ESH (2013)26a 
0.74 
(0.71-0.77) 
0.86 
(0.84-0.88) 
596 (54%) 203 (18%) 148 (13%) 151 (14%) 799 (73%) 0 (0%) 
NICE (2011)15 
0.73 
(0.70-0.76) 
0.84 
(0.82-0.87) 
513 (47%) 349 (32%) 2 (0.2%) 236 (21%) 862 (78%) 590 (54%) 
PROOF-BP 
(2016) 
0.75 
(0.72-0.78) 
0.87 
(0.85-0.89) 
720 (65%) 306 (28%) 45 (4%) 29 (3%) 1,026 (93%) 640 (58%) 
Data from HITS,18 TASMINH-SR,20 CAMBO12 and Oxford self-monitoring studies21 
AUC=Area Under the receiver operator characteristic Curve; CI=Confidence Intervals; ABPM=Ambulatory blood pressure monitoring; 
AHA=American Heart Association; CHEP=Canadian Hypertension Education Programme; European Society of Hypertension; NICE=National 
Institute for health and Care Excellence; PROOF-BP=PRedicting Out-of-OFfice Blood Pressure in clinic tool. 
aAnalysis only conducted in 1,098 patients due to missing data. 
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